Evidence map›Paper›PMID 40084481›Full record

ReviewJournal of hypertension2025

Blood pressure variability: a review.

Spoorthy Kulkarni, Gianfranco Parati, Sripal Bangalore, Grzegorz Bilo, Bum Joon Kim, Kazuomi Kario, Franz Messerli, George Stergiou, Jiguang Wang, William Whiteley and 2 more

Abstract readReview
In one paragraph

Review in Journal of hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. How useful is a casual BP measurement?Clinical medicine (London, England) · 2026
    Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Spoorthy KulkarniClinical Pharmacology Unit, Cambridge University Hospitals NHS Foundation Trust.
Gianfranco ParatiDepartment of Cardiology, IRCCS San Luca Hospiatal, Istituto Auxologico Italiano.
Sripal BangaloreBellevue Hospital Center and NYU School of Medicine, New York, New York, USA.
Grzegorz BiloDepartment of Cardiology, IRCCS San Luca Hospiatal, Istituto Auxologico Italiano.
Bum Joon KimDepartment of Neurology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea.
Kazuomi KarioDivision of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Franz MesserliUniversity of Bern, Switzerland and Jagiellonian University, Krakow, Poland.
George StergiouHypertension Center STRIDE-7, University of Athens, Greece.
Jiguang WangThe Shanghai Institute of Hypertension, Shanghai, China.
William WhiteleyCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Ian WilkinsonClinical Pharmacology Unit, Cambridge University Hospitals NHS Foundation Trust.
Peter S SeverNational Heart & Lung Institute, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood pressure variability (BPV) predicts cardiovascular events independent of mean blood pressure. BPV is defined as short-term (24-h), medium or long- term (weeks, months or years). Standard deviation, coefficient of variation and variation independent of the mean have been used to quantify BPV. High BPV is associated with increasing age, diabetes, smoking and vascular disease and is a consequence of premature ageing of the vasculature. Long-term BPV has been incorporated into cardiovascular risk models (QRISK) and elevated BPV confers an increased risk of cardiovascular outcomes even in subjects with controlled blood pressure. Long-acting dihydropyridine calcium channel blockers and thiazide diuretics are the only drugs that reduce BPV and for the former explains their beneficial effects on cardiovascular outcomes. We believe that BPV should be incorporated into blood pressure management guidelines and based on current evidence, long-acting dihydropyridines should be preferred drugs in subjects with elevated BPV.

Indexed as

Blood PressureHypertensionAntihypertensive AgentsCalcium Channel BlockersCardiovascular DiseasesHumansRisk FactorsAntihypertensive AgentsCalcium Channel BlockersASCOT studyblood pressure variabilitycoronary eventsstroke

Identifiers

PMID40084481
PMCPMC12052075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.